Klaus Linz

This inventor holds 35 USPTO granted patents and 40 published patent applications, plus 7 CIPO patents and 36 EPO patents, primarily in Pharmaceutical Composition. Top assignees: Gruenenthal Gmbh, Grunenthal Gmbh, Park Therapeutics, Inc.. Active years: 2008-2022.

USPTO Granted Patents = 35 (Patent Applications = 40)

% Patents Active = 54.3

CIPO Patents = 7 (Patent Applications = 13)

EPO Patents = 36 (Patent Applications = 33)

Average Co-Inventor Count = 5.7

ph-index = 7

Forward Citations = 181(Granted Patents)

Location History:

Wachtberg, DE (2011 - 2017)
Bonn, DE (2008 - 2018)
Rheinbach, DE (2014 - 2022)

Company Filing History:

Park Therapeutics, Inc.

patents

Years Active: 2008-2022

Loading Chart...

Areas of Expertise:

Pharmaceutical Composition

Spirocyclic Compounds

Azaspiro Derivatives

Cyclohexane Derivatives

Heteroaryl Compounds

4-Aminocyclohexane

Gabapentinoids

Antidepressants

Anticonvulsants

NSAR

Propionic Acid Derivatives

Substance Dependency

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11311504 - Pharmaceutical composition comprising (1R,4R)-6'- fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol (2022-04-26),

2. 10829480 - 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives (2020-11-10),

3. 10807989 - 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-20),

4. 10807988 - 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-20),

5. 10793556 - 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-06),

6. 10793528 - 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-06),

7. 10328055 - Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indo]-4-amine and antidepressants (2019-06-25),

8. 10214520 - Substituted azaspiro(4.5)decane derivatives (2019-02-26),

9. 10202345 - Substituted azaspiro(4.5)decane derivatives (2019-02-12),

10. 10076510 - Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative (2018-09-18),

11. 9862719 - Process or preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds (2018-01-09),

12. 9855286 - Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component (2018-01-02),

13. 9629825 - Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid (2017-04-25),

14. 9580386 - Substituted 4-aminocyclohexane derivatives (2017-02-28),

15. 9403767 - Substituted 4-aminocyclohexane derivatives (2016-08-02),

Title: Innovation in Pharmaceuticals: The Legacy of Klaus Linz

Introduction: Klaus Linz is a prominent inventor based in Wachtberg, Germany, recognized for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 35 patents, Linz has been instrumental in developing innovative compositions that address critical healthcare needs.

Latest Patents: Among Klaus Linz's latest patents is a pharmaceutical composition that combines (1R,4R)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine with paracetamol or propacetamol. This invention offers a novel approach to pain management by incorporating a first pharmacologically active ingredient with a second, enhancing therapeutic outcomes. Another notable patent is for 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, which detail their preparation and applications in the medicinal field, particularly for pain treatment.

Career Highlights: Over the years, Klaus Linz has been associated with leading pharmaceutical companies such as Grünenthal GmbH, where he played a pivotal role in medication innovation. His extensive research has significantly influenced drug development processes and has improved quality of life for many patients.

Collaborations: Throughout his career, Klaus Linz has collaborated with notable professionals, including Werner Guenter Englberger and Hans Schick. These partnerships have fostered an environment of creativity and progressive thinking, further advancing the pharmaceutical sector.

Conclusion: Klaus Linz's work in the pharmaceutical field exemplifies the impact inventors can have on healthcare. His 35 patents and collaborative efforts underline his dedication to innovation, promising new treatments that contribute to patient care and pain management. As he continues his journey, the medical community eagerly anticipates his future contributions to the industry.